Summary of quality of life in the ASCENT phase 3 clinical trial for people with metastatic triple-negative breast cancer
- PMID: 39324726
- PMCID: PMC11537291
- DOI: 10.1080/14796694.2024.2381408
Summary of quality of life in the ASCENT phase 3 clinical trial for people with metastatic triple-negative breast cancer
Abstract
What is this summary about?: A medicine called sacituzumab govitecan (brand name TRODELVY®) has been proven to be an effective treatment for metastatic triple-negative breast cancer (mTNBC for short). Metastatic breast cancer is cancer that has spread to other parts of the body. In mTNBC, the breast cancer cells do not have 3 common proteins on the cell surface, called receptors. mTNBC is more difficult to treat and more likely to come back than other types of breast cancer. The ASCENT study showed that participants with mTNBC treated with sacituzumab govitecan had a higher likelihood of living longer and delayed progression (worsening) of their cancer than those treated with standard chemotherapy. Here, we summarize the quality of life of participants with mTNBC in the ASCENT study. We compared quality of life between 236 participants treated with sacituzumab govitecan and 183 participants treated with standard chemotherapy. All participants previously received 2 or more chemotherapies that no longer controlled their cancer.
What are the key takeaways?: This analysis showed that participants treated with sacituzumab govitecan had better overall quality of life than participants treated with standard chemotherapy. They also had better "physical functioning", which is the ability to walk and do physical activities. Participants treated with sacituzumab govitecan maintained their overall quality of life for a longer time than those treated with standard chemotherapy. Participants treated with sacituzumab govitecan had less pain and were less tired than those treated with standard chemotherapy. On the other hand, participants treated with sacituzumab govitecan had worse diarrhea (loose or watery stools) and were more likely to have nausea/vomiting (feel sick or throw up) than participants treated with standard chemotherapy.
What were the main conclusions reported by the researchers?: Participants treated with sacituzumab govitecan had a higher likelihood of living longer and delayed progression (worsening) of their cancer. Participants also had a better overall quality of life, which was maintained (did not get worse) for a longer time. However, they experienced worsening of diarrhea and/or nausea/vomiting.Clinical Trial Registration: NCT02574455 (ASCENT) (ClinicalTrials.gov).
Keywords: breast; chemotherapy; clinical trials; metastasis.
Conflict of interest statement
S Loibl reports non-financial support from Daiichi-Sankyo, Immunomedics/Gilead Sciences, Inc., Novartis, Pfizer, Roche, and Seadgen. D Loirat is on the data safety monitoring board or advisory board of MSD. K Punie has participated on a data safety monitoring board or advisory board of Eli Lilly, Gilead Sciences, Inc, MSD, Novartis, Pierre Fabre, Roche, Teva, and Vifor Pharma; is a board member of the Belgian Society of Medical Oncology; and is a member of the ESMO Young Oncologists Committee and the ESMO Resilience Task Force committee. LA Carey reports participation on a data safety monitoring board or advisory board of Sanofi Aventis, Novartis, Genentech/Roche, GSK, AstraZeneca/Daiichi Sanyo, and Aptitude Health; and reports having a spouse who has served on the board of Falcon Therapeutics and who has had involvement in a neural stem cell therapy patent. L Gianni reports participation on the advisory boards of ADC Therapeutics, AstraZeneca, Celgene, Eli Lilly, G1 Therapeutics, Genentech, Genomic Health, MSD, Oncolytics Biotech, Odonate Therapeutics, Onkaido Therapeutics, Roche, Pfizer, Taiho Pharmaceutical, Hexal Sandoz, Seattle Genetics, Synthon, Zymeworks, Sanofi Aventis. PA Spears is on the advisory committee of real-world evidence for Pfizer, Inc. MJ Piccart is on the advisory boards of Debiopharm, Immunomedics, Immutep, Menarini, Odonate, Roche-Genentech, Seagen, and Seattle Genetics; has obtained support as an invited speaker from AstraZeneca, Lilly, MSD, Novartis, Pfizer, and Roche-Genentech; and is a member of the Board of Directors at Oncolytics. The authors have no other competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript apart from those disclosed.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
